ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer
- 1 January 2020
- journal article
- research article
- Published by Elsevier BV in Cancer Letters
- Vol. 473, 156-163
- https://doi.org/10.1016/j.canlet.2019.12.037
Abstract
No abstract availableFunding Information
- Academy of Finland
- Cancer Society of Finland
- Sigrid Juselius Foundation
- Jane and Aatos Erkko Foundation
- Finnish Cancer Organizations
- K. Albin Johansson Foundation
- Helsinki University Research Grants
This publication has 29 references indexed in Scilit:
- Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancerTherapeutic Advances in Gastroenterology, 2012
- Choosing the right cell line for breast cancer researchBreast Cancer Research, 2011
- Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancerCancer Letters, 2011
- Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivoBreast Cancer Research, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic targetAnnals of Oncology, 2008
- Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistanceMolecular Cancer Therapeutics, 2007
- Differential sensitivities of trastuzumab (Herceptin®)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitorsBreast Cancer Research and Treatment, 2005
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987